Biomarkers in Acute Heart Failure
Biomarkers in Acute Heart Failure: An International, Multi-Center Trial Evaluating the Prognostic and Diagnostic Utility of Biomarkers in Patients With Heart Failure Presenting With Shortness of Breath
Sponsor: Brahms AG
A observational or N/A phase clinical study on Heart Failure and Shortness of Breath, this trial is completed. The trial is conducted by Brahms AG and has accumulated 10 data snapshots since 2007. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Mar 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Brahms AG
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Athens, Greece, Baltimore, United States, Basel, Switzerland, Berlin, Germany, Christchurch, New Zealand, Cleveland, United States, Detroit, United States, Leicester, United Kingdom, Minneapolis, United States, Richmond, United States and 4 more location s